Preparation, Characterization and Immunostimulatory Effects of CRD2 and CRD3 from TNF Receptor-1 Encapsulated into Pegylated Liposomal Nanoparticles

Hatamihanza, Hamide; Alavi, Seyed Ebrahim; Shahmabadi, Hasan Ebrahimi; Akbarzadeh, Azim

doi:10.1007/s10989-019-09882-8

Cited by 12 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present study demonstrate that homogenous nanoparticles with a negative zeta potential and sizes ranging from 221 to 274 nm were formed (Table 1). Also, the loading of Cispt into liposome caused an increase in the size, indicating the encapsulation of the drug into nanoparticles [31]. In addition, the results show that PEGylation caused a decrease in the size of nanoparticles.…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 84%

“…In the present study, PLCispt was found to be more efficacious compared to LCispt in increasing the Cispt efficacy and reduction of tumor volume, as it caused 2.6-fold reduction in the tumor volume compared to LCispt, demonstrating the role of PEGylation in enhancing the potency of liposome nanoparticles after intraperitoneal administration. In this regard, the results of one study [54] showed that PEGylated liposomes could be detected in the blood 30 h after intraperitoneal injection, while this value for non-PEGylated liposome was 7 h. Therefore, coating the surfaces of liposomes with PEG improves carrier stability in blood circulation and extends the drug release [31], and as a result enhances the chance of drug delivery to the target site. Also, the results of the present study showed that the tumor number was significantly decreased in tumor-bearing rats receiving PLCispt compared to other groups (the tumor numbers in control, PBS, Cispt, LCispt, and PLCispt groups were 21.8 ± 1.1, 20 ± 0.9, 12.1 ± 0.6, 8.1 ± 0.4, and 5.3 ± 0.2, respectively).…”

Section: In Vivo Antitumor Efficacy Of the Formulationsmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder cancer (BC). Cispt was loaded into liposomes using reverse-phase evaporation method, and the formulations were characterized using dynamic light scattering, scanning electron microscopy, dialysis membrane, and Fourier-transform infrared spectroscopy (FTIR) methods. The results showed that the particles were formed in spherical monodispersed shapes with a nanoscale size (221–274 nm) and controlled drug release profile. The cytotoxicity effects of LCispt and PLCispt were assessed in an in vitro environment, and the results demonstrated that PLCispt caused a 2.4- and 1.9-fold increase in the cytotoxicity effects of Cispt after 24 and 48 h, respectively. The therapeutic and toxicity effects of the formulations were also assessed on BC-bearing rats. The results showed that PLCispt caused a 4.8-fold increase in the drug efficacy (tumor volume of 11 ± 0.5 and 2.3 ± 0.1 mm3 in Cispt and PLCispt receiver rats, respectively) and a 3.3-fold decrease in the toxicity effects of the drug (bodyweight gains of 3% and 10% in Cispt and PLCispt receiver rats, respectively). The results of toxicity were also confirmed by histopathological studies. Overall, this study suggests that the PEGylation of LCispt is a promising approach to achieve a nanoformulation with enhanced anticancer effects and reduced toxicity compared to Cispt for the treatment of BC.

show abstract

Section: Characterization Of Nanoparticlesmentioning

confidence: 84%

Section: In Vivo Antitumor Efficacy Of the Formulationsmentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…42 Results of previous studies also demonstrated that PEGylation of liposomes caused an increase in the biological half-life of the encapsulated drug and as a result an increase in drug efficacy. 43,44 In addition, DSPE-PEG-Mal linker was used to conjugate thiolated OX26 to the surface of liposomes as well. Maleimide (Mal) reacts rapidly and efficiently with the thiol group.…”

Section: Discussionmentioning

confidence: 99%

<p>In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin</p>

Ashrafzadeh¹,

Akbarzadeh²,

Heydarinasab³

et al. 2020

IJN

Self Cite

View full text Add to dashboard Cite

Background: Drug delivery systems have demonstrated promising results to cross bloodbrain barrier (BBB) and deliver the loaded therapeutics to the brain tumor. This study aims to utilize the transferrin receptor (TR)-targeted liposomal cisplatin (Cispt) for transporting Cispt across the BBB and deliver Cispt to the brain tumor. Methods: Targeted pegylated liposomal cisplatin (TPL-Cispt) was synthesized using reverse phase evaporation method and thiolated OX26 monoclonal antibody. The formulation was characterized in terms of size, size distribution, zeta potential, drug encapsulation and loading efficiencies, bioactivity, drug release profile, stability and cellular uptake using dynamic light scattering, flame atomic absorption spectroscopy (AAS), ELISA, dialysis membrane, and fluorescence assay. Next, the potency of the formulation to increase the therapeutic effects of Cispt and decrease its toxicity effects was evaluated in the brain tumorbearing rats through measuring the mean survival time (MST), blood factors and histopathological studies. Results: The results showed that TPL-Cispt with a size of 157±8 nm and drug encapsulation efficiency of 24%±1.22 was synthesized, that was biologically active and released Cispt in a slow-controlled manner. The formulation compared to Cispt-loaded PEGylated liposome nanoparticles (PL-Cispt) caused an increase in the cellular uptake by 1.43fold, as well as an increase in the MST of the brain tumor-bearing rats by 1.7-fold compared to the PL-Cispt (P<0.001). TPL-Cispt was potent enough to cause a significant decrease in Cispt toxicity effects (P<0.001). Conclusion: Overall, the results suggest that targeting the Cispt-loaded PEGylated liposome is a promising approach to develop formulation with enhanced efficacy and reduced toxicity for the treatment of brain tumor.

show abstract

“…This targeted approach is preferred for both acute and chronic wound care treatments. Novel drug delivery methods have been developed for bioactive proteins, such as peptides and GFs, along with advancements in antibacterial wound dressing techniques. Furthermore, a promising approach for wound treatment involves cell therapy and stem cell strategies .…”

Section: Drug Delivery Systems For Wound Healing and Skin Regenerationmentioning

confidence: 99%

Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations

Alavi,

Nisa

et al. 2024

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Human skin is the largest organ and outermost surface of the human body, and due to the continuous exposure to various challenges, it is prone to develop injuries, customarily known as wounds. Although various tissue engineering strategies and bioactive wound matrices have been employed to speed up wound healing, scarring remains a significant challenge. The wound environment is harsh due to the presence of degradative enzymes and elevated pH levels, and the physiological processes involved in tissue regeneration operate on distinct time scales. Therefore, there is a need for effective drug delivery systems (DDSs) to address these issues. The objective of this review is to provide a comprehensive exposition of the mechanisms underlying the skin healing process, the factors and materials used in engineering DDSs, and the different DDSs used in wound care. Furthermore, this investigation will delve into the examination of emergent technologies and potential avenues for enhancing the efficacy of wound care devices.

show abstract

Preparation, Characterization and Immunostimulatory Effects of CRD2 and CRD3 from TNF Receptor-1 Encapsulated into Pegylated Liposomal Nanoparticles

Cited by 12 publications

References 48 publications

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

<p>In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin</p>

Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations

Contact Info

Product

Resources

About